Blueprint Medicines Funding: $115M Raised, Series C (2014)
Blueprint Medicines is a Biotech company based in Cambridge, Massachusetts. It has raised $115M in total funding. Latest round: Series C.
Blueprint Medicines funding overview
Blueprint Medicines is a Biotech company based in Cambridge, Massachusetts. Blueprint Medicines has raised $115M in total disclosed funding. That places its disclosed total in the $100M–$250M range. Its most recent disclosed round is a Series C announced in November 2014. The round record for Blueprint Medicines runs through 2014; nothing later has been disclosed. Investors on record include BVF Partners, Casdin Capital, Cowen Healthcare Investments, F-Prime Capital, Nextech Invest, Perceptive Advisors and 6 others. 12 distinct backers are named across the disclosed rounds.
Blueprint Medicines at a glance
Total raised
$115M
Latest round
Series C
Latest round date
November 2014
Industry
Biotech
Headquarters
Cambridge, Massachusetts
Notable investors
BVF Partners, Casdin Capital, Cowen Healthcare Investments, F-Prime Capital, Nextech Invest, Perceptive Advisors, RA Capital Management, Redmile Group
Frequently asked about Blueprint Medicines funding
How much has Blueprint Medicines raised?
Blueprint Medicines has raised $115M in total disclosed funding across the rounds on record.
Who has invested in Blueprint Medicines?
BVF Partners, Casdin Capital, Cowen Healthcare Investments, F-Prime Capital, Nextech Invest, Perceptive Advisors are named among the investors backing Blueprint Medicines.
What was the latest Blueprint Medicines funding round?
The most recent disclosed round is a Series C, announced in November 2014.
Where is Blueprint Medicines based?
Blueprint Medicines is based in Cambridge, Massachusetts.
What sector does Blueprint Medicines operate in?
Blueprint Medicines is tracked under Biotech from Cambridge, Massachusetts, with $115M in disclosed funding.
When did Blueprint Medicines last raise?
The last disclosed Blueprint Medicines round closed in November 2014 at Series C.
Blueprint Medicines totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Cambridge below to benchmark round size and investor mix.
